Circulating Tumor Cell Isolation: A Marathon Race Worth Running

Lianidou, Evi

doi:10.1373/clinchem.2013.216010

Cited by 18 publications

(15 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Differences between our results and those of the literature may have been the result of divergences in patient populations, timepoints of blood sampling or sample volumes, reflecting a general lack of standardization in CTC analysis, as suggested by other authors [36,37]. However, another explanation could be the enrichment and staining method used: our procedure is not dependent on EpCAM only and can thus also enrich and detect EpCAM-negative/panCKpositive CTCs.…”

Section: Discussioncontrasting

confidence: 57%

Circulating tumor cells in early breast cancer: A connection with vascular invasion

et al. 2015

View full text Add to dashboard Cite

Section: Discussioncontrasting

confidence: 57%

Circulating tumor cells in early breast cancer: A connection with vascular invasion

et al. 2015

View full text Add to dashboard Cite

“…Unfortunately, after decades of exploration, our understanding of tumor metastasis is still far from complete, let alone enough for prevention and cure. Circulating tumor cells (CTCs) have recently been attracting great attention due to their key role in tumor metastasis, even though they were first discovered almost 150 years ago (3,4). Given the value of prognosis prediction of CTCs, the US Food and Drug Administration (FDA) has approved their clinical use in metastatic breast, colorectal and prostate cancers (5).…”

Section: Introductionmentioning

confidence: 99%

Circulating tumor cell clusters: What we know and what we expect (Review)

Hong

Fang

Zhang

2016

International Journal of Oncology

191

179

View full text Add to dashboard Cite

The major cause of cancer-associated mortality is tumor metastasis, a disease that is far from understood. Many studies have observed circulating tumor cells (CTCs) in patients' circulation systems, and a few latest investigations showed that CTC clusters have a potentially high capacity of metastasis. The capture and analysis of CTC clusters offer new insights into tumor metastasis and can facilitate the development of cancer treatments. We reviewed the research history of the CTC clusters, as well as the technologies used for detecting and isolating CTC clusters. In addition, we discuss the characteristics of CTC clusters and their roles in tumor dissemination. Clinical relevance of CTC clusters was also implicated in currently limited data. Moving forward, the next frontier in this field is to develop more efficient capture methods and decipher conundrums of characterization of CTC clusters. This will ultimately identify the clinical value of CTC clusters as a biomarker and therapeutic target.

show abstract

“… 4 , 5 As CTCs are gaining importance in understanding both the disease and therapeutic outcomes, new modalities are under development to detect, enumerate, and isolate CTCs from patient blood. 6 Many state-of-the-art CTC technologies have been elaborated for CTC detection in patients. 7 CTCs have been identified in PB in patients affected by the most disparate types of tumors, but there are only few evidences about their presence in blood samples collected from patients with a diagnosis of Ewing sarcoma (ES).…”

Section: Introductionmentioning

confidence: 99%

Detection of circulating tumor cells in liquid biopsy from Ewing sarcoma patients

Benini¹,

Gamberi²,

Cocchi³

et al. 2018

CMAR

View full text Add to dashboard Cite

BackgroundCirculating tumor cells (CTCs) analysis is a promising new diagnostic field to estimate risk and monitor treatment efficacy, metastatic relapse, and progression in cancer patients. The study aim was to isolate and characterize CTCs in blood samples of Ewing sarcoma (ES) patients exploiting two main characteristics: CD99 expression and presence of chromosomal translocations.Materials and methodsThe method isolated CTCs from peripheral blood (PB) of ES patients. Cell-surface CD99 was a useful marker for CTCs determined using immunomagnetic separation with microbeads and CD99 monoclonal antibody. We tested sensitivity and specificity by detecting CTCs in blood collected from healthy donors and randomly during therapy from 18 ES patients. Evidence of CTCs was confirmed by detection of specific molecular markers using quantitative and digital reverse transcription-polymerase chain reaction targeting EWSR1/FLI1 type 1 and type 2 or EWSR1/ETS-related gene transcripts type 1 and type 9e.ResultsFeasibility of finding CTCs in PB of ES patients by immunoseparation with CD99 antibody and magnetic microbeads was demonstrated for the first time. At molecular analysis, three PB specimens tested positive for chimeric EWSR1/FLI1 type 2 and one PB for chimeric EWSR1/FLI1 type 2. CTCs detection was found above a limit of detection of 1 cell/mL of PB.ConclusionCTCs in PB of ES patients can be identified by this method and in ES CTCs analysis can be used as a liquid biopsy approach for prognostic and predictive purposes. The potential clinical implications of CTCs in PB samples detected by the platform for CTC isolation with molecular confirmation during therapy require further evaluation.

show abstract

Circulating Tumor Cell Isolation: A Marathon Race Worth Running

Cited by 18 publications

References 17 publications

Circulating tumor cells in early breast cancer: A connection with vascular invasion

Circulating tumor cells in early breast cancer: A connection with vascular invasion

Circulating tumor cell clusters: What we know and what we expect (Review)

Detection of circulating tumor cells in liquid biopsy from Ewing sarcoma patients

Contact Info

Product

Resources

About